CLINICAL TRIALS PROFILE FOR ZOMACTON

All Clinical Trials for ZOMACTON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00250250 ↗	An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG	Completed	Ferring Pharmaceuticals	Phase 3	2005-10-01	Children with growth failure due to inadequate secretion of growth hormone or growth retardation due to Turner's syndrome are individually dosed and treated for 12 weeks
NCT00840944 ↗	A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height	Active, not recruiting	Belgian Study Group for Pediatric Endocrinology	Phase 4	2008-01-01	Estrogens are responsible for the disappearance of growth cartilage in the long bones at the end of the pubertal growth spurt both in boys and in girls. It is therefore hypothesized that stopping pubertal development and hence estrogen production, will prolong and increase the pubertal growth spurt, especially when growth hormone is given concommitantly. Boys in early puberty, with a bone age between 11 and 13 years and a predicted adult height below 163 cm or girls in early puberty with a bone age between 10 and 12 years and a predicted height under 151 cm will be treated with triptorelin 3.75 mg and Zomacton growth hormone for 4 years.
NCT00884000 ↗	A Study of Zomacton in Children With Growth Hormone Deficiency	Completed	Ferring Pharmaceuticals	Phase 3	2010-01-01	This trial is set up to compare Zomacton to Genotropin for the treatment of growth hormone deficiency in children. The children will be treated for 1 year. Half of the patients will be treated with Genotropin and half with Zomacton. During this time they will be dosed every day by themselves or their parents at home in the evening. There will be 138 patients in the trial from age 3 to age 11. The patients cannot have been treated before with growth hormone and the patients must have a proven growth hormone deficiency, this will be shown by a specific test that will be performed before the trial in the local clinic and once during the trial. During the time of the treatment the patients will come to visit the clinic every 3 months. At these visits their heights will be measured, blood samples will be taken, physical examinations will be performed and questions about their health will be asked. At 2 times in the trial they will have a hand x-ray taken to measure the bone age. At the end of the trial the patients will stop the treatment and continue on one of the marketed products available to treat growth hormone deficiency.
NCT01306357 ↗	Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device	Completed	Ferring Pharmaceuticals		2007-09-01	The purpose of this strictly observational, prospective, longitudinal study is to evaluate with sufficient precision the rate of overall treatment compliance from one year to 3 years of follow-up of the patients. Somatotropin is indicated in the long-term treatment of children with growth retardation related to a deficiency in secretion of growth hormone and in the long-term treatment of growth retardation related to Turner's syndrome confirmed by chromosomal analysis. These are the two indications of Zomacton® 4 mg and 10 mg injection solution. The use of the Zomajet® needle-free device (Zomajet® 2 Vision, reserved for the administration of Zomacton® 4 mg or of the Zomajet® Vision X needle-free device, reserved for the administration of Zomacton® 10 mg), allows the product to be administered by percutaneous transjection (needle-free) and can be used by the child directly or by the family after an initial training. In April 2004, the CEPP (Commission for the Evaluation of Products and Services) requested a follow-up of the cohort of patients using the Zomajet® 2 Vision system measuring the compliance and duration of use of the device. The number of patients initiated on Zomacton treatment using the Zomajet® needle-free device is estimated to 30. Over a period of inclusion of 3 years, we therefore estimate that 90 patients will be treated. In the cohort studied the patients will be followed-up for 1 year at least and for 3 years at the maximum. The rate of treatment compliance will be evaluated according to the ratio of the actual duration of administration over the total duration recommended by the physician during the observation period.
NCT01731028 ↗	Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton®	Withdrawn	Ferring Pharmaceuticals		2013-01-01	The purpose of this study is to investigate the long-term treatment with Zomacton® for pituitary short stature in children with insufficient growth hormone production and/or short stature caused by Turner's syndrome.
NCT02018172 ↗	Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device	Terminated	Ferring Pharmaceuticals		2014-07-01	The study is performed to collect long-term data on the treatment adherence and patient's acceptability when Zomacton®10 mg is administered with the Zomajet® Vision X device in patients with a growth hormone deficiency or Turner's syndrome.

Clinical Trial Conditions for ZOMACTON

Condition Name

Condition Name for ZOMACTON
Intervention	Trials
Growth Hormone Deficiency	3
Turner's Syndrome	3
Human Growth Hormone Deficiency	1
Idiopathic Short Stature	1

Condition MeSH

Condition MeSH for ZOMACTON
Intervention	Trials
Dwarfism, Pituitary	4
Endocrine System Diseases	3
Turner Syndrome	3
Primary Ovarian Insufficiency	3

Clinical Trial Locations for ZOMACTON

Trials by Country

Trials by Country for ZOMACTON
Location	Trials
Belgium	4
France	3
Israel	1
Russian Federation	1
Netherlands	1

Clinical Trial Progress for ZOMACTON

Clinical Trial Phase

Clinical Trial Phase for ZOMACTON
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2

Clinical Trial Status

Clinical Trial Status for ZOMACTON
Clinical Trial Phase	Trials
Completed	3
Active, not recruiting	1
Terminated	1

Clinical Trial Sponsors for ZOMACTON

Sponsor Name

Sponsor Name for ZOMACTON
Sponsor	Trials
Ferring Pharmaceuticals	5
Belgian Study Group for Pediatric Endocrinology	1

Sponsor Type

Sponsor Type for ZOMACTON
Sponsor	Trials
Industry	5
Other	1

ZOMACTON Market Analysis and Financial Projection

Last updated: April 29, 2026

ZOMACTON (somatropin) Clinical Trials Update, Market Analysis, and Projections

What is ZOMACTON and what is the core regulatory/product footprint?

ZOMACTON is a brand of somatropin (human growth hormone) marketed for pediatric growth failure and other indications requiring exogenous GH. Somatropin in the US is administered as a daily injection and is sold across multiple branded and authorized biosimilar products. ZOMACTON’s commercial footprint is shaped by (1) biosimilar competition for somatropin, (2) payer preference and contracting, (3) inventory and tender cycles for specialty pharmacies, and (4) lifecycle management after originator branding transitions.

Clinical development for ZOMACTON as a specific brand product is limited in recent years because somatropin’s active ingredient is mature and most new late-stage work in growth disorders has moved to newer formulations, delivery systems, and competitor molecules rather than brand-level refreshes. The remaining trial activity is largely tied to indication label maintenance, comparative PK/PD bridging, and new patient population expansion under the somatropin class.

---

What does the latest clinical-trials picture show for ZOMACTON (somatropin)?

A practical read-through for ZOMACTON-specific “trial updates” is to track (a) active/ongoing “somatropin” studies that commonly include brand arms and (b) label-relevant endpoints that drive payer access and prescribing behavior: height velocity, growth response (HtSDS), IGF-1 control, adherence/tolerability, and safety.

Current trial activity in somatropin generally clusters into four areas:

1. Pediatric growth disorders (GHD, Turner syndrome, SGA, idiopathic short stature in selected programs, and other GH-responsive syndromes) with endpoints such as height velocity and final height proxies.
2. Safety surveillance with AE/SAE capture, monitoring for intracranial hypertension, glucose metabolism changes, and malignancy signals where relevant.
3. Comparative bioavailability/PK, immunogenicity, and pharmacodynamic bridging for formulations and manufacturing changes (often using somatropin products with class comparators).
4. Treatment adherence and real-world response studies using registry or prospective observational designs, frequently focusing on day-by-day injection practices and persistence.

Because somatropin is mature, trial velocity at the brand level is low, while evidence generation continues under the broader somatropin category.

---

How are clinicians and payers likely to position ZOMACTON in 2025–2027?

ZOMACTON competes in a crowded somatropin market. Positioning is driven by:

• Contracting dynamics: payer formularies generally favor lower net-cost biosimilar/authorized alternatives after competitive entry and tendering.
• Patient access: insurer authorization often centers on pediatric height/growth velocity criteria, prior therapy rules, and required baseline documentation.
• Switching and interchangeability: forced switching risk affects adherence; clinicians often require stable response data and tolerability.

Net impact: ZOMACTON pricing and volume growth are constrained unless it holds a payer-specific niche (history-based contracts, channel relationships, or particular patient switching patterns).

---

Market Analysis: somatropin competitive structure and ZOMACTON demand mechanics

Who are the main competitors and how does the market price down?

The US somatropin market includes:

• Originator branded somatropin products
• Multiple authorized biosimilars
• Alternative GH therapies for certain growth disorders (in some segments), though most children with classic indications still use somatropin as first-line GH replacement.

Price-down mechanism: After biosimilar entries, originator brands often lose share due to:

• formulary tier placement changes,
• pharmacy benefit manager rebates,
• mandatory step edits or prior authorization tightening,
• substitution at pharmacy level depending on payer policy.

Business implication for ZOMACTON: demand is likely to be more stable than “growth,” with growth tied to (1) overall pediatric GHD incidence and diagnosis rates, (2) contract wins, and (3) persistence rather than new patient starts alone.

---

What are the market drivers for somatropin overall?

Demand drivers:

• Diagnosis rates for pediatric GH deficiency and related syndromes
• Guideline adherence and increased screening practices
• Long treatment duration (multi-year therapy creates stickiness once started)
• Payer coverage for pediatric growth disorders (authorization criteria strongly affects initiation)

Constraint drivers:

• Biosimilar economics and contracting pressure
• Switching friction (persistence impacts)
• Safety monitoring requirements that increase administrative burden and sometimes reduce uptake

---

Projections for ZOMACTON (volume, revenue, and share)

ZOMACTON’s future is best modeled as a mature, contract-driven share allocation inside the somatropin class rather than a category-growth story. Without brand-specific financial disclosures in this request, the cleanest projection is directional: share is pressured, revenue is stabilized by pricing and contract mix, and volume grows only marginally with total treated patients.

2025–2027 base-case directional outlook

• ZOMACTON volume: low-to-mid single-digit growth in treated patients is plausible, but much of this depends on payer contracts and switching behavior rather than brand differentiation.
• ZOMACTON share: slight decline vs the biosimilar set unless ZOMACTON holds premium-tier contracts.
• Revenue: likely tracks a combination of stable average net pricing and volume drift; total growth is more likely to be limited than category-driven.

What KPIs should be monitored to validate the projection?

• Share of prescriptions by plan tier (specialty pharmacy fulfillment and PBM reporting)
• Persistence at 12 and 24 months (drop-off after switching)
• Prior authorization pass rates by indication
• Average net price trends by payer cohort
• Dispense channel mix (specialty pharmacy vs direct hub contracting)

---

Key commercial and clinical implications for R&D or investment decisions

Is there evidence of “brand differentiation” in outcomes that can defend pricing?

For mature somatropin brands, defensibility tends to come from:

• stable injection experience, training materials, and patient support programs,
• consistent supply availability,
• payer-specific contract performance,
• and the absence of major safety signals that drive utilization controls.

Clinical response expectations across somatropin products tend to be similar when exposure and adherence are comparable, so brand advantage typically comes from commercial execution and access, not new clinical efficacy.

---

Where do new entrants or adjacent therapies most threaten ZOMACTON?

Threat vectors:

• More aggressive biosimilar contracting
• Newer GH delivery profiles (where they materially improve adherence or outcomes)
• Non-somatropin GH-related therapies that can substitute in selected indications

Net effect is reduced incremental start rates, forcing originator/brand incumbents to rely on persistence and contract retention.

---

Key Takeaways

• ZOMACTON is a mature somatropin brand operating in a saturated market with ongoing evidence generation at the somatropin class level rather than brand-level late-stage pivots.
• Clinical trial activity is largely indication-maintenance, bridging, safety surveillance, and adherence/real-world studies that align with payer endpoints like height velocity and IGF-1 control.
• Commercial outlook is contract-driven: biosimilar pressure limits share growth and shifts the game toward persistence, plan tier position, and net-price protection.
• 2025–2027 base-case is directional stability with mild pressure: volume growth is likely limited; revenue growth depends on maintaining favorable payer cohorts and reducing switching losses.

---

FAQs

1) What is ZOMACTON used for?

ZOMACTON is used for conditions requiring treatment with human growth hormone, including pediatric growth disorders where GH deficiency or GH responsiveness is indicated.

2) Why are brand-level ZOMACTON trial updates limited?

Somatropin is a mature active ingredient, so most new clinical evidence is built around class-level studies, comparability/bridging, safety monitoring, and formulation or delivery innovations rather than brand-specific efficacy breakthroughs.

3) How does biosimilar competition affect ZOMACTON?

It typically drives payer formulary tier downgrades, rebate renegotiations, and increased substitution, which pressures originator brand share and net pricing.

4) What clinical endpoints matter most for market access?

Payer and clinician decisions often hinge on height velocity and growth response metrics (such as HtSDS/height outcomes proxies), IGF-1 control, tolerability, and safety monitoring.

5) What should determine investment timing for ZOMACTON?

Contract performance, persistence at 12-24 months, and plan share trends within the specialty pharmacy ecosystem. Uptake changes usually follow PBM contracting cycles rather than new clinical data.

---

References

[1] FDA. Drug Approval Package: ZOMACTON (somatropin). U.S. Food and Drug Administration.
[2] DailyMed. ZOMACTON (somatropin) injection, for subcutaneous use: Prescribing Information. National Library of Medicine.
[3] EMA. Somatropin authorized products and regulatory assessments under European guidance. European Medicines Agency.
[4] ClinicalTrials.gov. Somatropin studies (ongoing and completed), search results filtered by indications and recruiting status. U.S. National Library of Medicine.